Additionally, the 36-month beta value for DYN is 1.17. There are mixed opinions on the stock, with 7 analysts rating it as a “buy,” 6 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for DYN is 85.23M and currently, short sellers hold a 17.43% ratio of that float. The average trading volume of DYN on May 22, 2025 was 2.49M shares.
DYN) stock’s latest price update
Dyne Therapeutics Inc (NASDAQ: DYN)’s stock price has gone decline by -4.70 in comparison to its previous close of 12.34, however, the company has experienced a 0.51% increase in its stock price over the last five trading days. globenewswire.com reported 2025-05-08 that – FDA (CDER) Type C meeting held in May 2025 for DYNE-101 in DM1 and Dyne plans to provide a regulatory update following receipt of meeting minutes –
DYN’s Market Performance
Dyne Therapeutics Inc (DYN) has seen a 0.51% rise in stock performance for the week, with a 18.67% gain in the past month and a -15.94% plunge in the past quarter. The volatility ratio for the week is 6.09%, and the volatility levels for the past 30 days are at 8.74% for DYN. The simple moving average for the last 20 days is 2.06% for DYN’s stock, with a simple moving average of -49.84% for the last 200 days.
Analysts’ Opinion of DYN
Many brokerage firms have already submitted their reports for DYN stocks, with BMO Capital Markets repeating the rating for DYN by listing it as a “Outperform.” The predicted price for DYN in the upcoming period, according to BMO Capital Markets is $50 based on the research report published on March 12, 2025 of the current year 2025.
Scotiabank, on the other hand, stated in their research note that they expect to see DYN reach a price target of $50. The rating they have provided for DYN stocks is “Sector Outperform” according to the report published on March 07th, 2025.
Robert W. Baird gave a rating of “Outperform” to DYN, setting the target price at $46 in the report published on December 13th of the previous year.
DYN Trading at 10.70% from the 50-Day Moving Average
After a stumble in the market that brought DYN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -75.22% of loss for the given period.
Volatility was left at 8.74%, however, over the last 30 days, the volatility rate increased by 6.09%, as shares surge +9.09% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -2.24% lower at present.
During the last 5 trading sessions, DYN rose by +0.51%, which changed the moving average for the period of 200-days by -71.20% in comparison to the 20-day moving average, which settled at $11.52. In addition, Dyne Therapeutics Inc saw -50.08% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DYN starting from Scalzo Richard William, who proposed sale 2,479 shares at the price of $11.82 back on May 16 ’25. After this action, Scalzo Richard William now owns shares of Dyne Therapeutics Inc, valued at $29,313 using the latest closing price.
Beskrovnaya Oxana, the Officer of Dyne Therapeutics Inc, proposed sale 2,589 shares at $11.82 during a trade that took place back on May 16 ’25, which means that Beskrovnaya Oxana is holding shares at $30,614 based on the most recent closing price.
Stock Fundamentals for DYN
The total capital return value is set at -0.58. Equity return is now at value -64.01, with -59.05 for asset returns.
Based on Dyne Therapeutics Inc (DYN), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -13.7.
Currently, EBITDA for the company is -315.18 million with net debt to EBITDA at 1.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 20.35.
Conclusion
In conclusion, Dyne Therapeutics Inc (DYN) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
